{"created":"2023-07-27T06:39:05.922137+00:00","id":27412,"links":{},"metadata":{"_buckets":{"deposit":"7807d650-af0d-458c-96d4-662d80836fcc"},"_deposit":{"created_by":3,"id":"27412","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"27412"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00027412","sets":["1777:1778:1779"]},"author_link":["141"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"1893","bibliographicPageStart":"1887","bibliographicVolumeNumber":"98","bibliographic_titles":[{"bibliographic_title":"日本内科学会雑誌 = The Journal of the Japanese Society of Internal Medicine"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"現在わが国では，EGFR-TKIとしては非小細胞肺癌に対してゲフィチニブ（商品名イレッサ®）とエルロチニブ（商品名タルセバ®）が，VEGFR-TKIとしては腎細胞癌に対してソラフェニブ（商品名ネクサバール®）とスニチニブ（商品名スーテント®）が認可されている．また，EGFRとerbB2の阻害薬であるラパチニブが乳癌に対して，ソラフェニブが肝細胞癌に対して承認申請されている．さらに，臨床開発が進められているものとしては不可逆的EGFR-TKI，EGFRとVEGFRに対するdual inhibitor，VEGFRファミリーに強い活性を有する阻害薬などが注目されている．","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本内科学会 = The Japanese Society of Internal Medicine"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2169/naika.98.1887","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/browse/naika/-char/ja/","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.naika.or.jp/","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://ci.nii.ac.jp/naid/10025193289","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © The Japanese Society of Internal Medicine 日本内科学会"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN00195836","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0021-5384","subitem_source_identifier_type":"ISSN"}]},"item_4_text_2":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_text_value":"II．分子標的薬の開発と臨床: 1.開発段階の分子標的薬"},{"subitem_text_value":"Molecular Targeted Drugs in the Developmental Stage. 1) VEGFR-TKI and EGFR-TKI"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"矢野, 聖二"}],"nameIdentifiers":[{},{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-05"}],"displaytype":"detail","filename":"CA-PR-YANO-S-1887.pdf","filesize":[{"value":"387.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"CA-PR-YANO-S-1887.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/27412/files/CA-PR-YANO-S-1887.pdf"},"version_id":"b5a0fba9-6fdf-423d-9531-c6a887b7a3eb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"開発段階の分子標的薬　1）VEGFR-TKIとEGFR-TKI","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"開発段階の分子標的薬　1）VEGFR-TKIとEGFR-TKI"}]},"item_type_id":"4","owner":"3","path":["1779"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-05"},"publish_date":"2017-10-05","publish_status":"0","recid":"27412","relation_version_is_last":true,"title":["開発段階の分子標的薬　1）VEGFR-TKIとEGFR-TKI"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-27T21:06:45.131089+00:00"}